Macropore Inc. IR-Pages
MacroPore Biosurgery to Webcast 2004 First Quarter Results on May 7, 2004
Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
——————————————————————————–
MacroPore Biosurgery to Webcast 2004 First Quarter Results on May 7, 2004
San Diego, CA, May 03, 2004 – MacroPore Biosurgery, Inc. (Frankfurt: XMP)
(MACP.DE) (XMP:GR), today announced it will release its financial results for
the first quarter of 2004 on Friday, May 7, 2004 at approximately 4:00 p.m.
Central European Summer Time (CEST) or 10:00 a.m. Eastern Daylight Time (EDT).
The announcement will be followed by a conference call at 4:30 p.m. CEST or
10:30 a.m. EDT hosted by Christopher J. Calhoun, President and Chief Executive
Officer of MacroPore Biosurgery.
The conference call will be webcast live and may be accessed on the Investor
Relations section of the Company’s website at http://www.macropore.com . An
archived version of the webcast will be available on the same website 60 Minutes
after the call. A telephone replay will be available for 24 hours. To access
the replay, please call +49 / 69 / 58 99 90 568 (PIN: 132524#).
Contact:
MacroPore Biosurgery, Inc.
Tom Baker
Media & U.S. Investors
Tel. +1-858-458-0900
tbaker@macropore.com
MacroPore Biosurgery, Inc.
Stefanie Bacher
European Investors
Tel. +1-858-362-0365
sbacher@macropore.com
edicto GmbH
Axel Mühlhaus/Sönke Knop
European Investor &
Press Agency
Tel.: +49 (0) 60 84 94 85-90
kontakt@edicto.de
About MacroPore Biosurgery, Inc.
MacroPore Biosurgery (Frankfurt: XMP) (MACP.DE) (XMP:GR) is focused on the
discovery and development of regenerative medicine technologies. Our surgical
implants, which represent one of the latest advancements in spine and orthopedic
medicine, are manufactured by us and distributed exclusively through Medtronic
Sofamor Danek. We are conducting research and development for an autologous,
homologous-use, cell-based technology for the regeneration and repair of damaged
tissues throughout the body. We are currently targeting the repair of
cardiovascular tissues that are damaged after a myocardial infarction. For
further information please visit our web site http://www.macropore.com .
end of message, (c)DGAP 03.05.2004
——————————————————————————–
WKN: 940682; ISIN: USU553961025; Index: NEMAX 50
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-
Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart
032012 Mai 04
Aktuelle News
Aktuelle Berichte
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden